Toward a glioblastoma vaccine: Promise and potential pitfalls

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4240-4243

  Fine, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; TUMOR VACCINE; CANCER VACCINE;

AVULAVIRUS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE SYSTEM; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; VACCINATION; ACTIVE IMMUNIZATION; CELL CULTURE; IMMUNOLOGY; NOTE; PROGNOSIS; SURVIVAL RATE;

AVULAVIRUS; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ACTIVE; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 16544389191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.927     Document Type: Editorial

References (5)

1. Stupp R, Mason WP, Van Den Bent MJ, et al: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Proc Am Soc Clin Oncol 23:1, 2004 (suppl; abstr 2)
2. Steiner HH, Bonsanto MM, Beckhove P, et al: Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to access feasibility, safety, and clinical benefit. J Clin Oncol 22:4272-4281, 2004
3. Dudley ME, Wunderlich JR, Bobbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
4. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 30:10-14, 2003 (6 suppl 19).
5. Curran WJ Jr, Scott CB, Norton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993